Row:(MILLIONS OF DOLLARS AND SHARES, EXCEPT PER SHARE DATA) 	2019 	2018 	2017
Row:Revenue $ 	6,260 $ 	5,825 $ 	5,307
Row:Costs and expenses:
			Row:Cost of sales(a) 	1,992 	1,911 	1,775
Row:Selling, general and administrative expenses(a) 	1,638 	1,484 	1,334
Row:Research and development expenses(a) 	457 	432 	382
Row:Amortization of intangible assets 	155 	117 	91
Row:Restructuring charges and certain acquisition-related costs 	51 	68 	19
Row:Interest expense, net of capitalized interest 	223 	206 	175
Row:Other (income)/deductions––net 	(57) 	(83) 	6
Row:Income before provision for taxes on income 	1,801 	1,690 	1,525
Row:Provision for taxes on income 	301 	266 	663
Row:Net income before allocation to noncontrolling interests 	1,500 	1,424 	862
Row:Less: Net loss attributable to noncontrolling interests 	— 	(4) 	(2)
Row:Net income attributable to Zoetis $ 	1,500 $ 	1,428 $ 	864
Row:Earnings per share attributable to Zoetis Inc. stockholders:
			Row:Basic $ 	3.14 $ 	2.96 $ 	1.76
Row:Diluted $ 	3.11 $ 	2.93 $ 	1.75
Row:Weighted-average common shares outstanding:
			Row:Basic 	478.128 	483.063 	489.918
Row:Diluted 	481.787 	486.898 	493.161
Row:Dividends declared per common share $ 	0.692 $ 	0.542 $ 	0.441
Row:(MILLIONS OF DOLLARS, EXCEPT PER SHARE DATA) 	December 31, December 31,
2019 2018
Row:Assets
Cash and cash equivalents(a) 	Row:$ Short-term investments 	1,934 $ 1,602
— 99
Row:Accounts receivable, less allowance for doubtful accounts of $21 in 2019 and $24 in 2018 Inventories Other current assets 	1,086 1,036
1,410 1,391
318 271
Row:Total current assets 	4,748 4,399
Row:Property, plant and equipment, less accumulated depreciation of $1,737 in 2019 and $1,599 in 2018 	1,940 1,658
Row:Operating lease right of use assets 	189 —
Row:Goodwill Identifiable intangible assets, less accumulated amortization 	2,592 2,519
1,890 2,046
Row:Noncurrent deferred tax assets Other noncurrent assets Total assets $ 	88 61
98 94
11,545 $ 10,777
Row:Liabilities and Equity
	Row:Short-term borrowings $ 	— $ 9
Row:Current portion of long-term debt Accounts payable 	500 —
301 313
Row:Dividends payable 	95 79
Row:Accrued expenses 	543 487
Row:Accrued compensation and related items 	276 266
Row:Income taxes payable 	36 35
Row:Other current liabilities 	55 34
Row:Total current liabilities 	1,806 1,223
Row:Long-term debt, net of discount and issuance costs Noncurrent deferred tax liabilities 	5,947 6,443
434 474
Row:Operating lease liabilities 	164 —
Row:Other taxes payable 	257 265
Row:Other noncurrent liabilities 	229 187
Row:Total liabilities 	8,837 8,592
Row:Commitments and contingencies (Note 18)
	Row:Stockholders' equity:
Common stock, $0.01 par value: 6,000,000,000 authorized, 501,891,243 and 501,891,243 shares issued;
475,528,210 and 479,562,326 shares outstanding at December 31, 2019 and 2018, respectively 	5 5
Row:Treasury stock, at cost, 26,363,033 and 22,328,917 shares of common stock at December 31, 2019 and 2018,
respectively 	(2,042) (1,487)
Row:Additional paid-in capital Retained earnings 	1,044 1,026
4,427 3,270
Row:Accumulated other comprehensive loss 	(726) (629)
Row:Total equity 	2,708 2,185
Row:Total liabilities and equity $ 	11,545 $ 10,777
Row:(a) As of December 31, 2019 and December 31, 2018, includes $2 million and $5 million, respectively, of restricted cash.
	Row:Common stock, $0.01 par value: 6,000,000,000 authorized, 501,891,243 and 501,891,243 shares issued;
475,528,210 and 479,562,326 shares outstanding at December 31, 2019 and 2018, respectively 	5 5
Row:Treasury stock, at cost, 26,363,033 and 22,328,917 shares of common stock at December 31, 2019 and 2018,
respectively 	(2,042) (1,487)
Row:Additional paid-in capital 	1,044 1,026
Row:Retained earnings 	4,427 3,270
Row:Accumulated other comprehensive loss 	(726) (629)
Row:Total equity 	2,708 2,185
Row:Total liabilities and equity 	$ 11,545 $ 10,777
Row:(MILLIONS OF DOLLARS) 	Year Ended 2019 	December 31,
2018 2017
Row:Operating Activities
		Row:Net income before allocation to noncontrolling interests $ Adjustments to reconcile net income before noncontrolling interests to net cash provided by operating activities:
	1,500 $ 	1,424 $ 862
Row:Depreciation and amortization expense 	412 	308 242
Row:Share-based compensation expense 	67 	53 44
Row:Asset write-offs and asset impairments 	7 	4 3
Row:Net (gain)/loss on sales of assets 	(20) 	(42) 11
Row:Provision for losses on inventory Deferred taxes(a) 	68 (79) 	54 54
(112) 127
Row:Employee benefit plan contribution from Pfizer Inc. 	3 	3 3
Row:Other non-cash adjustments Other changes in assets and liabilities, net of acquisitions and divestitures
	(12) 	(14) 10
Row:Accounts receivable Inventories 	(69) (104) 	(67) (50)
61 19
Row:Other assets 	(51) 	(42) (16)
Row:Accounts payable 	(10) 	37 (10)
Row:Other liabilities 	91 	56 (38)
Row:Other tax accounts, net 	(8) 	67 85
Row:Net cash provided by operating activities 	1,795 	1,790 1,346
Row:Investing Activities
		Row:Capital expenditures Acquisition of Abaxis, net of cash acquired 	(460) — 	(338) (224)
(1,884) —
Row:Other acquisitions 	(195) 	(114) (82)
Row:Proceeds from maturities and redemptions of investments 	101 	28 —
Row:Net proceeds on swaps designated as net investment hedges 	37 	— —
Row:Net proceeds from sales of assets Other investing activities 	21 (8) 	56 37
(7) (1)
Row:Net cash used in investing activities 	(504) 	(2,259) (270)
Row:Financing Activities
		Row:(Decrease)/increase in short-term borrowings, net 	(9) 	8 —
Row:Principal payments on long-term debt Proceeds from issuance of long-term debt—senior notes, net of discount and fees Payment of contingent consideration related to previously acquired assets Share-based compensation-related proceeds, net of taxes paid on withholding shares and excess tax benefits 	— — (9) 7 	— (750)
1,485 1,231
(12) (7)
19 24
Row:Purchases of treasury stock Cash dividends paid 	(626) (314) 	(698) (500)
(243) (206)
Row:Acquisition of a noncontrolling interest 	— 	(26) (43)
Row:Net cash (used in)/provided by financing activities 	(951) 	533 (251)
Row:Effect of exchange-rate changes on cash and cash equivalents 	(8) 	(26) 12
Row:Net increase in cash and cash equivalents Cash and cash equivalents at beginning of period 	332 1,602 	38 837
1,564 727
Row:Cash and cash equivalents at end of period $ 	1,934 $ 	1,602 $ 1,564
Row:Cash paid during the period for:
	Row:Income taxes 	$ 418 $ 336 $ 455
Row:Interest, net of capitalized interest 	247 190 167
Row:Non-cash transactions:
	Row:Capital expenditures 	$ 7 $ 7 $ 5
Row:Contingent purchase price consideration 	23 — 29
Row:Dividends declared, not paid 	95 79 61
